U.S. Markets close in 2 hrs 8 mins
  • S&P 500

    4,277.04
    -28.16 (-0.65%)
     
  • Dow 30

    34,007.17
    -144.84 (-0.42%)
     
  • Nasdaq

    12,945.35
    -157.20 (-1.20%)
     
  • Russell 2000

    2,020.53
    -0.82 (-0.04%)
     
  • Crude Oil

    86.64
    +0.11 (+0.13%)
     
  • Gold

    1,788.70
    -1.00 (-0.06%)
     
  • Silver

    20.00
    -0.09 (-0.45%)
     
  • EUR/USD

    1.0168
    -0.0003 (-0.0305%)
     
  • 10-Yr Bond

    2.9040
    +0.0800 (+2.83%)
     
  • Vix

    19.82
    -0.13 (-0.65%)
     
  • GBP/USD

    1.2096
    +0.0001 (+0.0109%)
     
  • USD/JPY

    134.8020
    +0.5870 (+0.4374%)
     
  • BTC-USD

    23,413.77
    -438.61 (-1.84%)
     
  • CMC Crypto 200

    556.58
    -16.24 (-2.83%)
     
  • FTSE 100

    7,540.93
    +4.87 (+0.06%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DANVERS, Mass., February 08, 2022--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference (virtual) on Thursday, February 17, 2022 at 10:40am.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including with respect to Abiomed's development of existing and new products, the Company's commercial growth, future business opportunities and pending regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements due to a number of factors, including uncertainties related to the scope, extent and duration of the impact of the COVID-19 pandemic, development, testing and related regulatory approvals, including the possibility of future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological changes, governmental requirements, litigation, future capital requirements and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent filings with the SEC. Readers of this press release are advised not to evaluate forward-looking statements, which reflect information available only as of the date of this release, as reliable information. The Company is under no obligation to release updates to these forward-looking statements to reflect events or circumstances occurring after the date of the release or as a result of the impact of unforeseen events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005815/en/

Contacts

Todd Trapp
Vice President and Chief Financial Officer
978-646-1680
ttrapp@abiomed.com